GLYC - グリコ・ミメティックス (GlycoMimetics Inc.) グリコ・ミメティックス

 GLYCのチャート


 GLYCの企業情報

symbol GLYC
会社名 GlycoMimetics Inc (グリコ・ミメティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 GlycoMimetics Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate GMI-1070 (Rivipansel) for the treatment of vaso-occlusive crisis (VOC) a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271 a specific E-selectin inhibitor to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML) multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate GMI-1359 that targets both E-selectin and a chemokine receptor CXCR4. The Company is also advancing other preclinical-stage programs which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.   グリコ・ミメティックスは希少薬の発見と開発を行う米国のバイオ医薬品会社。鎌状赤血球病患者の血管閉鎖性発作の治療薬GMI-1070、急性骨髄性白血病と血液凝固障害の治療薬GMI-1271の治験を行う。また、緑膿菌毒性因子をタ―ゲットにした治療薬の開発を行う。   GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
本社所在地 9708 Medical Center Drive Rockville MD 20850 USA
代表者氏名 M. James E. Barrett M.ジェームスE.バレット
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-243-1201
設立年月日 37712
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.glycomimetics.com
nasdaq_url https://www.nasdaq.com/symbol/glyc
adr_tso
EBITDA EBITDA(百万ドル) -41.46510
終値(lastsale) 13.62
時価総額(marketcap) 586439976.54
時価総額 時価総額(百万ドル) 609.26030
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 379.82560
当期純利益 当期純利益(百万ドル) -39.99956
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 GlycoMimetics Inc revenues was not reported. Net loss increased 42% to $22.8M. Higher net loss reflects researcg and development expense balanc increase of 59% to $17.5M (expense) General_Administrative Expe increase of 26% to $4.3M (expense) Stock-based Compensation in R&D increase of 36% to $853K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.64 to -$0.59.

 GLYCのテクニカル分析


 GLYCのニュース

   GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020  2020/07/24 13:15:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able
   GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020  2020/05/15 16:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24. During the June session, GlycoMimetics will present preclinical data that further support the potential of the Company’s compounds to be used in the treatment of acute myeloid leukemia (AML)
   GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders  2020/05/08 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expe
   GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020  2020/05/01 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million. “During the quarter, patient enrollment continued on track in GlycoMimetics’ Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute
   Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications  2020/04/30 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 2020, issue of Nature Communications. The paper outlines how uproleselan, an investigational, first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in acute myeloid leukemia (AML) through the key mechanism of targeted E-selectin inhibition.1 “Thi
   GlycoMimetics to Report Second Quarter Financial Results on July 31, 2020  2020/07/24 13:15:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 1677593. Participants are encouraged to connect 15 minutes in advance of the call to ensure that all callers are able
   GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020  2020/05/15 16:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24. During the June session, GlycoMimetics will present preclinical data that further support the potential of the Company’s compounds to be used in the treatment of acute myeloid leukemia (AML)
   GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders  2020/05/08 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expe
   GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020  2020/05/01 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million. “During the quarter, patient enrollment continued on track in GlycoMimetics’ Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute
   Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications  2020/04/30 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 2020, issue of Nature Communications. The paper outlines how uproleselan, an investigational, first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in acute myeloid leukemia (AML) through the key mechanism of targeted E-selectin inhibition.1 “Thi
   GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020  2020/05/15 16:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24. During the June session, GlycoMimetics will present preclinical data that further support the potential of the Company’s compounds to be used in the treatment of acute myeloid leukemia (AML)
   GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders  2020/05/08 12:30:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meeting. The virtual Annual Meeting is expe
   GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020  2020/05/01 11:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million. “During the quarter, patient enrollment continued on track in GlycoMimetics’ Phase 3 registration program evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) as well as in our collaboration with the National Cancer Institute
   Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications  2020/04/30 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-stage clinical candidate, uproleselan, are published in the April 27, 2020, issue of Nature Communications. The paper outlines how uproleselan, an investigational, first-in-class, targeted inhibitor of E-selectin, can reduce chemoresistance in acute myeloid leukemia (AML) through the key mechanism of targeted E-selectin inhibition.1 “Thi
   GlycoMimetics to Report First Quarter Financial Results on May 1, 2020  2020/04/24 13:00:00 Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4567397. A webcast replay will be available via the “Investors” tab on the GlycoMimetics website for 30 days following t

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 グリコ・ミメティックス GLYC GlycoMimetics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)